• 1
    Half EE,Arber N. Chemoprevention of colorectal cancer: two steps forward, one step back? Future Oncol 2006; 2: 697704.
  • 2
    Reddy BS,Hirose Y,Lubet R,Steele V,Kelloff G,Paulson S,Seibert K,Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000; 60: 2937.
  • 3
    Baek SJ,Kim KS,Nixon JB,Wilson LC,Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001; 59: 9018.
  • 4
    Baek SJ,Wilson LC,Lee CH,Eling TE. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002; 301: 112631.
  • 5
    Kim KS,Baek SJ,Flake GP,Loftin CD,Calvo BF,Eling TE. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 2002; 305: 138898.
  • 6
    Kim KS,Yoon JH,Kim JK,Baek SJ,Eling TE,Lee WJ,Ryu JH,Lee JG,Lee JH,Yoo JB. Cyclooxygenase inhibitors induce apoptosis in oral cavity cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Biochem Biophys Res Commun 2004; 325: 1298303.
  • 7
    Kim JS,Baek SJ,Sali T,Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 2005; 4: 48793.
  • 8
    Shim M,Eling TE. Protein kinase C-dependent regulation of NAG-1/placental bone morphogenic protein/MIC-1 expression in LNCaP prostate carcinoma cells. J Biol Chem 2005; 280: 1863642.
  • 9
    Baek SJ,Wilson LC,Eling TE. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002; 23: 42532.
  • 10
    Wilson LC,Baek SJ,Call A,Eling TE. Non-steroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003; 105: 74753.
  • 11
    Newman D,Sakaue M,Koo JS,Kim KS,Baek SJ,Eling TE,Jetten AM. Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in normal human tracheobronchial epithelial and lung carcinoma cells by retinoids. Mol Pharmacol 2003; 63: 55764.
  • 12
    Lee SH,Kim JS,Yamaguchi K,Eling TE,Baek SJ. Indole-3-carbinol and 3,3′-diindolylmethan induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005; 328: 639.
  • 13
    Baek SJ,Kim JS,Nixon JB,DiAugustine RP,Eling TE. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004; 279: 688392.
  • 14
    Yamaguchi K,Lee SH,Eling TE,Baek SJ. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 2006; 5: 135261.
  • 15
    Lee SH,Yamaguchi K,Kim JS,Eling TE,Safe S,Park Y,Baek SJ. Conjugated linoleic acid stimulates an antitumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 2006; 27: 97281.
  • 16
    Kim CH,Song KS,Kim KS,Kim JY,Lee BJ,Lee JG,Yoon JH. Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol 2005; 125: 2016.
  • 17
    Fan GK,Imanaka M,Yang B,Takenaka H. Characteristics of nasal inverted papilloma and its malignant transformation: a study of cell proliferation and programmed cell death. Am J Rhinol 2006; 20: 3603.
  • 18
    Katori H,Nozawa A,Tsukuda M. Increased expression of matrix metalloproteinae-2 and 9 and human papilloma virus infection are associated with malignant transformation of sinonasal inverted papilloma. JSurg Oncol 2006; 93: 805.
  • 19
    Katori H,Nozawa A,Tsukuda M. Markers of malignant transformation of sinonasal inverted papilloma. Eur J Surg Oncol 2005; 31: 90511.
  • 20
    Kim KS,Shin JH,Baek SJ,Yoon JH. Expression of non-steroidal anti-inflammatory drug-activated gene-1 in human nasal mucosa and cultured nasal epithelial cells: a preliminary investigation. Acta Otolaryngol 2003; 123: 85761.
  • 21
    Eling TE,Baek SJ,Shim M,Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. J Biochem Mol Biol 2006; 39: 64955.
  • 22
    Baek SJ,Eling TE. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 2006; 45: 116.
  • 23
    Chan CC,Boyce S,Brideau C,Charleson S,Cromlish W,Ethier D,Evans J,Ford-Hutchsinson AW,Forrest MJ,Gauthier JY,Gordon R,Gresser M, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furonone]: a potent and orally active cyclooxygenase-2 inhibitor. pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290: 55160.
  • 24
    Kato M,Nishida S,Kitasato H,Sakata N,Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol 2001; 52: 167985.
  • 25
    Martinez JM,Sali T,Okazaki R,Anna C,Hollingshead M,Hose C,Monks A,Walker NJ,Baek SJ,Eling TE. Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth. J Pharmacol Exp Ther 2006; 318: 899906.
  • 26
    Baek SJ,Okazaki R,Lee SH,Martinez J,Kim JS,Yamaguchi K,Mishina Y,Martin DW,Shoieb A,McEntee MF,Eling TE. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006; 131: 155360.
  • 27
    Brown DA,Ward RL,Buckhaults P,Lie T,Romans KE,Hawkins NJ. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9: 264250.
  • 28
    Lee DH,Yang Y,Lee SJ,Kim KY,Koo TH,Shin SM,Song KS,Lee YH,Kim YJ,Lee JJ,Choi I,Lee JH. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 464855.
  • 29
    Welsh JB,Sapinoso LM,Su AI,Kern SG,Wang-Rodriguez J,Moskaluk CA,Frierson HF,Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001; 61: 59748.
  • 30
    Alvan G,Orme M,Bertilsson L,Ekstrand R,Palmer L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther 1975; 18: 36473.
  • 31
    Duggan DE,Hogans AF,Kwan KC,McMahon FG. The metabolism of indomethacin in man. J Pharmacol Exp Ther 1972; 181: 56375.
  • 32
    Skinhoj A,Bechgaard H,Chasseaud LF,Brodie RR,Sharman JM,Taylor T,Hunter JO. The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation. Int J Clin Pharmacol Ther Toxicol 1984; 22: 55761.
  • 33
    Kwan KC,Breault GO,Umbenhauer ER,McMahon FG,Duggan DE. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm 1976; 4: 25580.